What it isSystemic retinoid normalizing keratinization; severe psoriasis, particularly pustular and erythrodermic.
Why this oneIt is not immunosuppressive, so it can be used where biologics are contraindicated, including in HIV.
What limits it⚑ Teratogenicity persists because alcohol converts it to etretinate; pregnancy must be avoided for three years. Hyperlipidemia and dryness occur.
FDA-approved for
severe psoriasis (1996)
Off-label
lichen planus
chemoprophylaxis of skin cancer in transplant recipients
BOXED WARNING Teratogenic — contraindicated in pregnancy; females must not become pregnant during therapy or for ≥3 years after, must use 2 effective contraceptives, and must avoid ethanol (forms long-lived etretinate). Prescribe only via P.P.E.T. program.
FDA dosing
Population
Start
Target
Max
Severe psoriasis
Adult
25–50 mg QD with main meal
25–50 mg QD
Renal Contraindicated in severely impaired kidney function
Hepatic Contraindicated in severely impaired liver function
Instructions
Take as a single daily dose with the main meal.
Dispense no more than a 1-month supply; provide Medication Guide at each dispensing.
Females of childbearing potential: no ethanol during therapy and for 2 months after.
Contraindications
Pregnancy (teratogenic — see Boxed Warning)
Severely impaired liver or kidney function
Chronic abnormally elevated blood lipid values
Concomitant methotrexate — increased risk of hepatitis
Concomitant tetracyclines — both can cause increased intracranial pressure
Microdosed “minipill” progestin preparations not recommended as contraception — acitretin interferes with their contraceptive effect
Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.